HB Wealth Management LLC lifted its stake in shares of Boston Scientific Co. (NYSE:BSX – Get Rating) by 80.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 11,318 shares of the medical equipment provider’s stock after purchasing an additional 5,041 shares during the period. HB Wealth Management LLC’s holdings in Boston Scientific were worth $524,000 as of its most recent filing with the SEC.
Several other large investors have also modified their holdings of BSX. Acadian Asset Management LLC acquired a new stake in Boston Scientific during the first quarter worth about $35,000. Massmutual Trust Co. FSB ADV raised its stake in Boston Scientific by 68.4% during the third quarter. Massmutual Trust Co. FSB ADV now owns 1,000 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 406 shares during the period. CVA Family Office LLC raised its stake in Boston Scientific by 952.6% during the third quarter. CVA Family Office LLC now owns 1,000 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 905 shares during the period. Adirondack Trust Co. raised its stake in Boston Scientific by 126.0% during the third quarter. Adirondack Trust Co. now owns 1,130 shares of the medical equipment provider’s stock worth $44,000 after acquiring an additional 630 shares during the period. Finally, Romano Brothers AND Company acquired a new stake in Boston Scientific during the fourth quarter worth about $46,000. Institutional investors own 90.23% of the company’s stock.
Boston Scientific Trading Up 0.9 %
Shares of Boston Scientific stock opened at $50.03 on Friday. The firm has a market capitalization of $71.91 billion, a PE ratio of 111.18, a price-to-earnings-growth ratio of 2.29 and a beta of 0.79. The company has a current ratio of 1.51, a quick ratio of 1.02 and a debt-to-equity ratio of 0.51. The firm’s 50 day moving average is $47.42 and its 200 day moving average is $44.73. Boston Scientific Co. has a 1 year low of $34.98 and a 1 year high of $50.21.
Insiders Place Their Bets
In other Boston Scientific news, CAO Jonathan Monson sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, March 31st. The shares were sold at an average price of $50.00, for a total transaction of $250,000.00. Following the sale, the chief accounting officer now directly owns 34,868 shares of the company’s stock, valued at approximately $1,743,400. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, EVP Arthur C. Butcher sold 27,000 shares of the business’s stock in a transaction that occurred on Friday, February 3rd. The shares were sold at an average price of $48.74, for a total value of $1,315,980.00. Following the transaction, the executive vice president now owns 23,392 shares in the company, valued at approximately $1,140,126.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Jonathan Monson sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, March 31st. The stock was sold at an average price of $50.00, for a total transaction of $250,000.00. Following the completion of the transaction, the chief accounting officer now owns 34,868 shares in the company, valued at approximately $1,743,400. The disclosure for this sale can be found here. Insiders have sold 130,885 shares of company stock valued at $6,204,217 in the last ninety days. 0.71% of the stock is currently owned by insiders.
Analyst Ratings Changes
Several equities research analysts recently weighed in on BSX shares. Morgan Stanley increased their price objective on shares of Boston Scientific from $50.00 to $56.00 and gave the stock an “overweight” rating in a research note on Friday, January 6th. UBS Group initiated coverage on shares of Boston Scientific in a research note on Tuesday. They issued a “buy” rating and a $57.00 price target on the stock. Needham & Company LLC boosted their target price on Boston Scientific from $48.00 to $53.00 and gave the stock a “buy” rating in a report on Thursday, February 2nd. Argus boosted their target price on Boston Scientific from $50.00 to $55.00 in a report on Friday, February 17th. Finally, Raymond James lifted their price target on shares of Boston Scientific from $54.00 to $56.00 and gave the stock a “strong-buy” rating in a research report on Thursday, February 2nd. One analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $51.82.
Boston Scientific Profile
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Urology and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions.
Featured Articles
- Get a free copy of the StockNews.com research report on Boston Scientific (BSX)
- What is a Gold IRA, and is it a Viable Investment?
- Is Braze, Inc Ready To Rocket Higher?
- Mullen Automotive Makes Deliveries; Short-Squeeze Possible
- Can Frontline Maintain This Momentum?
- Walmart Shares Jump on Evercore Analyst Upgrade
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
